CFFT Awards Corbus $5 Million to Develop Cystic Fibrosis Drug
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) has granted a $5 million development award to clinical stage drug developer Corbus Pharmaceuticals Holdings to support the development process of its investigational drug Resunab to treat cystic fibrosis (CF). The funding from the CFFT, which is the non-profit drug discovery and development affiliate of…